MX2020002645A - Pridopidina para el tratamiento de las discinesias inducidas por fármacos. - Google Patents
Pridopidina para el tratamiento de las discinesias inducidas por fármacos.Info
- Publication number
- MX2020002645A MX2020002645A MX2020002645A MX2020002645A MX2020002645A MX 2020002645 A MX2020002645 A MX 2020002645A MX 2020002645 A MX2020002645 A MX 2020002645A MX 2020002645 A MX2020002645 A MX 2020002645A MX 2020002645 A MX2020002645 A MX 2020002645A
- Authority
- MX
- Mexico
- Prior art keywords
- subject
- pridopidine
- drug induced
- treating
- treating drug
- Prior art date
Links
- YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 title abstract 2
- 229950003764 pridopidine Drugs 0.000 title abstract 2
- 208000009985 drug-induced dyskinesia Diseases 0.000 title 1
- 208000012661 Dyskinesia Diseases 0.000 abstract 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 2
- 208000016285 Movement disease Diseases 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229960004502 levodopa Drugs 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La invención proporciona un método para tratar a un sujeto que padece un trastorno del movimiento inducido por fármacos que incluye discinesia inducida por levodopa, que comprende administrar periódicamente al sujeto en necesidad del mismo una cantidad de pridopidina efectiva para tratar al sujeto. La invención proporciona además un método para tratar a un sujeto con riesgo de desarrollar un trastorno del movimiento inducido por fármacos, que incluye discinesia inducida por levodopa. La invención también proporciona composiciones farmacéuticas adecuadas para llevar a cabo estos métodos y envases que contienen dichas composiciones farmacéuticas.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762556314P | 2017-09-08 | 2017-09-08 | |
US201862649184P | 2018-03-28 | 2018-03-28 | |
PCT/US2018/048920 WO2019050775A1 (en) | 2017-09-08 | 2018-08-30 | PRIDOPIDINE FOR THE TREATMENT OF DYSKINESIC INDUCED BY A MEDICINAL PRODUCT |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020002645A true MX2020002645A (es) | 2021-06-10 |
Family
ID=63684481
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020002645A MX2020002645A (es) | 2017-09-08 | 2018-08-30 | Pridopidina para el tratamiento de las discinesias inducidas por fármacos. |
Country Status (10)
Country | Link |
---|---|
US (2) | US20190231768A1 (es) |
EP (1) | EP3678664A1 (es) |
JP (1) | JP2020533296A (es) |
CN (1) | CN111343982A (es) |
AU (1) | AU2018329628B2 (es) |
BR (1) | BR112020004622A2 (es) |
CA (1) | CA3075020C (es) |
IL (1) | IL273044A (es) |
MX (1) | MX2020002645A (es) |
WO (1) | WO2019050775A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG188298A1 (en) | 2010-09-03 | 2013-04-30 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
US11090297B2 (en) * | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
JP7278210B2 (ja) | 2016-08-24 | 2023-05-19 | プリレニア ニューロセラピューティクス リミテッド | ジストニアを治療するためのプリドピジンの使用 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
WO2006040155A1 (en) | 2004-10-13 | 2006-04-20 | Neurosearch Sweden Ab | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine |
SE529246C2 (sv) * | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
RU2470013C2 (ru) | 2007-04-12 | 2012-12-20 | НСАБ, Филиаль ау НьюроСёрч Свиден АБ, Сверийе | N-оксидные и/или ди-n-оксидные производные стабилизаторов/модуляторов рецепторов дофамина, проявляющие улучшенные профили сердечно-сосудистых побочных эффектов |
CN101765428A (zh) * | 2007-06-18 | 2010-06-30 | A·卡尔森研究股份有限公司 | 多巴胺稳定剂的用途 |
US20110206782A1 (en) | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
WO2011107583A1 (en) | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
US20130216856A1 (en) | 2010-07-02 | 2013-08-22 | Marco Burtchen | Mechanical component and method of surface hardening |
SG188298A1 (en) | 2010-09-03 | 2013-04-30 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
WO2013034622A1 (en) | 2011-09-07 | 2013-03-14 | Neurosearch A/S | Polymorphic form of pridopidine hydrochloride |
MX347209B (es) * | 2011-12-08 | 2017-04-19 | Teva Pharmaceuticals Int Gmbh | La sal de bromhidrato de pridopidina. |
MX2014011971A (es) | 2012-04-04 | 2015-01-16 | Ivax Int Gmbh | Composiciones farmaceuticas para terapia de combinacion. |
SG11201509729YA (en) | 2013-06-21 | 2015-12-30 | Teva Pharmaceuticals Int Gmbh | Use of high dose pridopidine for treating huntington's disease |
DK177976B8 (en) | 2013-07-10 | 2021-04-22 | Jasopels As | Apparatus and method for stretching a pelt on a pelt board |
PE20161220A1 (es) | 2014-01-22 | 2016-11-23 | Teva Pharmaceuticals Int Gmbh | Formulaciones de pridopidina de liberacion modificada |
JP6526695B6 (ja) | 2014-03-10 | 2019-06-26 | アプライド マテリアルズ インコーポレイテッドApplied Materials,Incorporated | 多重荷電粒子ビームリソグラフィのためのピクセルブレンディング |
TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
US9796673B2 (en) | 2014-12-22 | 2017-10-24 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
EP4282479A3 (en) | 2015-02-25 | 2024-02-21 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
US20170020854A1 (en) | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
AU2017223838B2 (en) | 2016-02-24 | 2022-09-29 | Prilenia Neurotherapeutics Ltd. | Treatment of neurodegenerative eye disease using pridopidine |
IL311081A (en) | 2016-08-24 | 2024-04-01 | Prilenia Neurotherapeutics Ltd | Use of pyridofidine to treat functional decline |
JP7278210B2 (ja) | 2016-08-24 | 2023-05-19 | プリレニア ニューロセラピューティクス リミテッド | ジストニアを治療するためのプリドピジンの使用 |
CN109952100A (zh) | 2016-09-15 | 2019-06-28 | 普瑞尼亚医疗发展有限公司 | 普利多匹定用于治疗焦虑和抑郁的用途 |
WO2018053275A1 (en) | 2016-09-16 | 2018-03-22 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for the treatment of familial dysautonomia |
IL268125B2 (en) | 2017-01-20 | 2023-04-01 | Prilenia Neurotherapeutics Ltd | Pridopidine for the treatment of fragile x syndrome |
ES2938546T3 (es) | 2017-08-14 | 2023-04-12 | Prilenia Neurotherapeutics Ltd | Método de tratamiento de la esclerosis lateral amiotrófica con pridopidina |
AU2018326596B2 (en) | 2017-08-30 | 2021-07-08 | Prilenia Neurotherapeutics Ltd. | High concentration dosage forms of pridopidine |
DE102018204527A1 (de) | 2017-09-18 | 2019-03-21 | SEs Solutions GmbH | Dachhalterung für ein Automobil |
-
2018
- 2018-08-30 AU AU2018329628A patent/AU2018329628B2/en active Active
- 2018-08-30 JP JP2020513603A patent/JP2020533296A/ja active Pending
- 2018-08-30 BR BR112020004622-1A patent/BR112020004622A2/pt active Search and Examination
- 2018-08-30 EP EP18778648.8A patent/EP3678664A1/en active Pending
- 2018-08-30 WO PCT/US2018/048920 patent/WO2019050775A1/en unknown
- 2018-08-30 CN CN201880072818.0A patent/CN111343982A/zh active Pending
- 2018-08-30 CA CA3075020A patent/CA3075020C/en active Active
- 2018-08-30 MX MX2020002645A patent/MX2020002645A/es unknown
-
2019
- 2019-04-08 US US16/377,577 patent/US20190231768A1/en not_active Abandoned
- 2019-06-11 US US16/436,947 patent/US11000519B2/en active Active
-
2020
- 2020-03-03 IL IL273044A patent/IL273044A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3075020A1 (en) | 2019-03-14 |
AU2018329628B2 (en) | 2021-04-22 |
EP3678664A1 (en) | 2020-07-15 |
CA3075020C (en) | 2021-12-07 |
US20190231768A1 (en) | 2019-08-01 |
CN111343982A (zh) | 2020-06-26 |
JP2020533296A (ja) | 2020-11-19 |
WO2019050775A1 (en) | 2019-03-14 |
US11000519B2 (en) | 2021-05-11 |
BR112020004622A2 (pt) | 2020-09-24 |
US20190350914A1 (en) | 2019-11-21 |
IL273044A (en) | 2020-04-30 |
AU2018329628A1 (en) | 2020-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
MX2017007321A (es) | Terapias de combinacion. | |
BR112018003984A2 (pt) | anticorpos | |
EA201890571A1 (ru) | Способы и композиции для лечения нарушения, ассоциированного с геном пропротеинконвертазы субтилизин/кексинового типа (pcsk9) | |
BR112014028017A2 (pt) | composto, composição farmacêutica, método para tratar um distúrbio, método para reduzir a quantidade il-17 em um indivíduo e método para inibir a atividade de ror | |
BR112018073920A2 (pt) | inibidores de pd-1/pd-l1 para tratamento de câncer". | |
BR112016029713A2 (pt) | métodos para o tratamento de sobrepeso ou obesidade | |
MX2020011783A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
EA201691454A1 (ru) | Композиции придопидина модифицированного высвобождения | |
MX2019001286A (es) | Composicion de cannabis. | |
EA201590388A1 (ru) | Способы лечения таупатии | |
MX2019002190A (es) | Uso de pridopidina para tratar distonías. | |
BR112016020618A8 (pt) | oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido | |
BR112014021498A2 (pt) | composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado | |
IN2015DN03219A (es) | ||
MX2020002645A (es) | Pridopidina para el tratamiento de las discinesias inducidas por fármacos. | |
BR112017003571A2 (pt) | terapia combinada | |
BR112017009584A2 (pt) | tratamento de retinite pigmentosa com n-acetilcisteína amida | |
EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
EA036102B9 (ru) | Терапевтические средства с углевод-опосредованной адресной доставкой | |
MD20160007A2 (ro) | Inhibitori ai RORC2 şi metode de utilizare a acestora | |
BR112019005040A2 (pt) | aplicação de pridopidina para tratamento de síndrome de rett | |
BR112017014793A2 (pt) | regime de dosagem para antagonistas de madcam | |
BR112019023948A2 (pt) | tratamento de cistos epiteliais por injeção intracística de partículas antineoplásicas | |
MX2019003703A (es) | Método seguro y eficaz para tratar la psoriasis con el anticuerpo específico anti-il23. |